QUININE
Cette fiche confirme une dénomination commune officielle d’ingrédient pour l’étiquetage des produits cosmétiques de l’UE. Elle ne confirme pas à elle seule que la substance est autorisée, non restreinte ou sûre.
Aperçu des preuves mondiales
L’identité résolue présente des preuves réglementaires correspondantes dans 8 des 13 jeux de données de marchés indexés : 7 fiches de pays et 1 fiches d’annexes de l’UE. Chaque résultat et chaque lacune de preuves sont énumérés ci-dessous.
Identité résolue de la substance
Cinchonan-9-ol, 6'-methoxy-, (8.alpha., 9R)-
Note de restriction de l’inventaire : III/21
9 noms correspondants ou signalés
Preuves réglementaires dans les 13 marchés
Ouvrez chaque fiche correspondante pour connaître son champ d’application, sa concentration, ses conditions, ses avertissements et la version de la source officielle.
Balayez ou faites défiler horizontalement pour voir la couverture des jeux de données et les actions suivantes.
| Marché | Résultat | Fiches | Jeu de données | Signification / action suivante |
|---|---|---|---|---|
| European Union EU | Soumise à restrictions | 1Ouvrir la fiche 1 | Complete annex dataset Regulation (EC) 1223/2009 consolidated to 1 May 2026 | Examinez chaque fiche associée et ses conditions exactes. |
| Great Britain GB | Restricted | 1Ouvrir la fiche 1 | Complete consolidated annex dataset GB retained Regulation 1223/2009 schedules, effective 15 August 2026 | Examinez chaque fiche associée et ses conditions exactes. |
| Canada CA | Aucune correspondance trouvée | 0 | Complete Hotlist snapshot Health Canada Cosmetic Ingredient Hotlist, 13 August 2025 | The Hotlist is an administrative compliance tool, not an exhaustive safety approval list. |
| New Zealand NZ | Restricted | 1Ouvrir la fiche 1 | Complete schedules dataset Cosmetic Products Group Standard schedules effective 1 January 2026 | Examinez chaque fiche associée et ses conditions exactes. |
| ASEAN ASEAN | Restricted | 1Ouvrir la fiche 1 | Complete regional annex dataset ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026 | Examinez chaque fiche associée et ses conditions exactes. |
| China CN | Aucune correspondance trouvée | 0 | Complete prohibited catalogues plus official-source workflow NMPA 2021 banned catalogues plus dynamic IECIC List I/List II system current since 2025 | IECIC listing is not blanket approval; absence may require the new cosmetic ingredient route, and restrictions are checked separately. |
| Japan JP | Aucune correspondance trouvée | 0 | Complete Standards appendices dataset MHLW Standards for Cosmetics official English source and Japanese amendments checked for the imported snapshot | The Japanese text and subsequent notices are canonical; no local match is not a product-compliance conclusion. |
| South Korea KR | Restricted | 1Ouvrir la fiche 1 | Complete current appendix dataset MFDS Notice 2026-19, effective 18 March 2026 | Examinez chaque fiche associée et ses conditions exactes. |
| United States US | Aucune correspondance trouvée | 0 | Complete enumerated federal ingredient rules eCFR Title 21 issue date 27 August 2026 | FDA has no general approved-cosmetic-ingredient catalogue; absence from these sections is not approval or proof of safety. |
| Australia AU | Restricted | 1Ouvrir la fiche 1 | Complete cosmetic-relevant Poisons Standard subset plus official workflow Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026 | Examinez chaque fiche associée et ses conditions exactes. |
| Brazil BR | Aucune correspondance trouvée | 0 | Complete prohibited dataset plus current restricted-list workflow ANVISA RDC 1.029/2026 and RDC 1.030/2026, published 15 June 2026 | RDC 1.030/2026 amends rather than replaces the prohibited baseline, and the second restricted-list revision was still under consultation in July 2026. |
| India IN | Restricted | 1Ouvrir la fiche 1 | Complete current Part 2 dataset plus official workflow for Parts 1, 3 and 4 Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022) | Examinez chaque fiche associée et ses conditions exactes. |
| Saudi Arabia SA | Restricted | 1Ouvrir la fiche 1 | Complete official list index SFDA live prohibited/restricted lists, snapshot 30 August 2026 | Examinez chaque fiche associée et ses conditions exactes. |
Fiches de marché correspondantes et conditions
Great Britain
GB retained Regulation 1223/2009 schedules, effective 15 August 2026New Zealand
Cosmetic Products Group Standard schedules effective 1 January 2026ASEAN
ASEAN Cosmetic Directive annexes 2026-1, 22 June 2026South Korea
MFDS Notice 2026-19, effective 18 March 2026Australia
Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026India
Cosmetics Rules 2020 plus current BIS IS 4707 parts (1:2020, 2:2025, 3:2025, 4:2022)Saudi Arabia
SFDA live prohibited/restricted lists, snapshot 30 August 2026Preuves exactes des annexes II à VI
QUININE
Champ d’application du produit : (a) Hair rinse-off products (b) Hair leave-on products
Concentration maximale : (a) 0.5% (as quinine base) (b) 0.2% (as quinine base)
Identité et propriétés chimiques

Quinine
Quinine is a cinchona alkaloid that is cinchonidine in which the hydrogen at the 6-position of the quinoline ring is substituted by methoxy. It has a role as a non-narcotic analgesic, an antimalarial and a muscle relaxant. It is a conjugate base of a quinine(1+). It derives from a hydride of an (8S)-cinchonan. — ChEBI
- Nom IUPAC
- (R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-methoxyquinolin-4-yl)methanol
- Formule moléculaire
- C20H24N2O2
- Masse moléculaire
- 324.4 g/mol
- Masse exacte
- 324.183778013 Da
- XLogP3
- 2,9
- Surface polaire topologique
- 45,6 Ų
- Donneurs de liaisons hydrogène
- 1
- Accepteurs de liaisons hydrogène
- 4
- Unités covalentes
- 1
- Stéréocentres définis
- 4
Également connu sous le nom de
16 autres noms signalés
Identifiants de bases de données externes
Preuves issues de bases de données scientifiques complémentaires
NIH PubChem PUG-View
Attributed physical-property, hazard, environmental and use annotations.
- Color/Form: Triboluminescent, orthorhombic needles from absolute alcohol Source: Hazardous Substances Data Bank (HSDB)
- Color/Form: Bulky, white, amorphous powder or crystalline alkaloid Source: Hazardous Substances Data Bank (HSDB)
- Color/Form: CRYSTALS TURN BROWN ON EXPOSURE TO AIR Source: Hazardous Substances Data Bank (HSDB)
- Basic pKa: 8.56 Source: ChEMBL
- Basic pKa: 8.55 Source: ChEMBL
- Dissociation Constants: pK1 (18 °C) = 5.07; pK2 = 9.7 Source: Hazardous Substances Data Bank (HSDB)
- LogP: 3.44 Source: DrugBank
- LogP: log Kow = 3.44 Source: Hazardous Substances Data Bank (HSDB)
- LogP: 2.6 Source: Human Metabolome Database (HMDB)
- Melting Point: 57 °C Source: DrugBank
- Melting Point: 177 °C (some decomposition) Source: Hazardous Substances Data Bank (HSDB)
- Melting Point: Microcrystalline powder; mp: 57 °C; efflorescent; loses one water molecule in air, two water molecules over sulfuric acid; anhydrous at 125 °C /Quinine trihydrate/ Source: Hazardous Substances Data Bank (HSDB)
- Melting Point: 57 °C Source: Human Metabolome Database (HMDB)
- Odor: ODORLESS Source: Hazardous Substances Data Bank (HSDB)
- Physical Description: Solid Source: Human Metabolome Database (HMDB)
- Refractive Index: INDEX OF REFRACTION: 1.625 Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 500 mg/L (at 15 °C) Source: DrugBank
- Solubility: In water, 500 mg/L at 15 °C Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 1 g dissolves in: 1900 mL water, 760 mL boiling water Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 1 g dissolves in: 80 mL benzene (18 mL at 50 °C), 1.2 mL chloroform, 250 mL dry ether, 20 mL glycerol, 0.8 mL alcohol, 1900 mL of 10% ammonia water; almost insoluble in petroleum ether Source: Hazardous Substances Data Bank (HSDB)
- Solubility: Soluble in ether, chloroform, carbon disulfide, glycerol, alkalies, and acids (with formation of salts) Source: Hazardous Substances Data Bank (HSDB)
- Solubility: Sol in pyrimidine Source: Hazardous Substances Data Bank (HSDB)
- Solubility: 3.34e-01 g/L Source: Human Metabolome Database (HMDB)
- pH: pH of saturated aqueous solution = 8.8 Source: Hazardous Substances Data Bank (HSDB)
- Carcinogen Classification: No indication of carcinogenicity to humans (not listed by IARC). Source: Toxin and Toxin Target Database (T3DB)
- Exposure Routes: Oral Source: Toxin and Toxin Target Database (T3DB)
- Signal: Danger Source: European Chemicals Agency (ECHA)
- GHS Hazard Statements: H302 (22.9%): Harmful if swallowed [Warning Acute toxicity, oral]; H315 (28.4%): Causes skin irritation [Warning Skin corrosion/irritation]; H317 (99.5%): May cause an allergic skin reaction [Warning Sensitization, Skin]; H319 (28.4%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334 (83.1%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Source: European Chemicals Agency (ECHA)
- Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P270, P271, P272, P280, P284, P301+P317, P302+P352, P304+P340, P305+P351+P338, P321, P330, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) Source: European Chemicals Agency (ECHA)
- ECHA C&L Notifications Summary: Aggregated GHS information provided per 201 reports by companies from 10 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.; Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website. Source: European Chemicals Agency (ECHA)
- Signal: Warning Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
- GHS Hazard Statements: H302: Harmful if swallowed [Warning Acute toxicity, oral]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin] Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
- Precautionary Statement Codes: P261, P264, P270, P272, P280, P301+P317, P302+P352, P321, P330, P333+P317, P362+P364, and P501 (click each P-code to see the statement) Source: Hazardous Chemical Information System (HCIS), Safe Work Australia
- Signal: Danger Source: Hazardous Substances Data Bank (HSDB)
- GHS Hazard Statements: H315: Causes skin irritation [Warning Skin corrosion/irritation]; H317: May cause an allergic skin reaction [Warning Sensitization, Skin]; H319: Causes serious eye irritation [Warning Serious eye damage/eye irritation]; H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory] Source: Hazardous Substances Data Bank (HSDB)
- Precautionary Statement Codes: P233, P260, P261, P264, P264+P265, P271, P272, P280, P284, P302+P352, P304+P340, P305+P351+P338, P321, P332+P317, P333+P317, P337+P317, P342+P316, P362+P364, P403, and P501 (click each P-code to see the statement) Source: Hazardous Substances Data Bank (HSDB)
- Health Effects: It is usual for quinine in therapeutic doses to cause cinchonism; in rare cases, it may even cause death (usually by pulmonary edema). Quinine can worsen hemoglobinuria, myasthenia gravis and optic neuritis. It can cause paralysis if accidentally injected into a nerve, and is extremely toxic in overdose[Wikipedia] Source: Toxin and Toxin Target Database (T3DB)
- Toxicity Summary: IDENTIFICATION AND USE: Quinine is a bulky, white, amorphous powder or crystalline alkaloid, used as medication: non-narcotic analgesics; antimalarial; central muscle relaxants. It is also used as flavor in carbonated beverages. HUMAN EXPOSURE AND TOXICITY: Serious hypersensitivity reactions, including anaphylactic shock, anaphylactoid reactions, urticaria, serious skin rashes, angioedema, facial edema, bronchospasm, and pruritus, have been reported with quinine. In addition, thrombocytopenia, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP), immune thrombocytopenic purpura, blackwater fever, disseminated intravascular coagulation, leukopenia, neutropenia, granulomatous hepatitis, and acute interstitial nephritis have been reported and may also be due to hypersensitivity reactions to the drug. Potentially fatal cardiac arrhythmias, including torsades de pointes and ventricular fibrillation, have been reported rarely during quinine therapy. At least 1 case of fatal ventricular arrhythmia has been reported in a geriatric patient with preexisting prolonged QT interval treated with IV quinine sulfate for Plasmodium falciparum malaria. Visual impairment can range Source: Hazardous Substances Data Bank (HSDB)
- Toxicity Summary: The theorized mechanism of action for quinine and related anti-malarial drugs is that these drugs are toxic to the malaria parasite. Specifically, the drugs interfere with the parasite's ability to break down and digest hemoglobin. Consequently, the parasite starves and/or builds up toxic levels of partially degraded hemoglobin in itself. Source: Toxin and Toxin Target Database (T3DB)
- Uses: Medicine (antimalarial) as the alkaloid or as numerous salts and derivatives; flavoring in carbonated beverages Source: Hazardous Substances Data Bank (HSDB)
- Uses: Flavor in carbonated beverages. Source: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION Source: Hazardous Substances Data Bank (HSDB)
- Uses: MEDICATION (VET) Source: Hazardous Substances Data Bank (HSDB)
- Uses: For more Uses (Complete) data for QUININE (8 total), please visit the HSDB record page. Source: Hazardous Substances Data Bank (HSDB)
- Uses: Use (kg; approx.) in Germany (2009): >5000; Use (kg) in USA (2002): 56800; Consumption (g per capita; approx.) in Germany (2009): 0.0611; Consumption (g per capita) in the USA (2002): 0.201; Calculated removal (%): 41.8 Source: NORMAN Suspect List Exchange
- Uses: For the treatment of malaria and leg cramps. Used as an antipyretic (fever-reducing), antimalarial, analgesic (painkilling), and anti-inflammatory. It is also used as a flavor component of tonic water and bitter lemon. Source: Toxin and Toxin Target Database (T3DB)
Mis en correspondance par: Existing checksum-valid CAS to unique PubChem CID match. Récupéré le: 2026-08-31. Ouvrir la fiche source
Les classifications scientifiques et les annotations de danger apportent du contexte et ne remplacent pas la décision réglementaire propre au marché indiquée ci-dessus.
Couverture des sources complémentaires et état des correspondances
| Source | Résultat | Vérifié |
|---|---|---|
| NIH PubChem PUG-View | Correspondance exacte | 2026-08-31 |
Une absence de correspondance enregistrée est une preuve utile que la source a été vérifiée ; ce n’est pas l’affirmation que la substance n’existe pas ailleurs.
Récupéré depuis NIH PubChem le 2026-08-31 par correspondance CAS à somme de contrôle valide. Les propriétés chimiques ne remplacent pas la décision réglementaire de cette page.
Recherche complémentaire sur la substance auprès de sources faisant autorité
Chaque lien lance une recherche de cette identité dans la source concernée. Un lien est une piste de recherche, et non l’affirmation que la source détient une fiche exacte. Ce qu’est chaque source et sa valeur juridique
Aller plus loin avec cette fiche
Source officielle et champ d’application
Importé de la décision d’exécution (UE) 2025/1175 de la Commission (version du jeu de données EU 2025/1175). Le glossaire fournit les dénominations communes des ingrédients pour la liste d’ingrédients exigée par l’article 19, paragraphe 1, point g) ; ce n’est ni une liste d’autorisation ni une liste de sécurité.
Ouvrir la décision officielle